Pharmaceutical

ASCO 2025: AstraZeneca's Breakthrough Innovations in Cancer Treatment Leading Global Oncology Advances ASCO Market Trend AstraZeneca Discover AstraZeneca’s groundbreaking cancer research at ASCO 2025, featuring innovative therapies in breast, lung, and digestive cancers. Leading global oncology with advanced treatments and strategic local-global integration.
MoonLake Immunotherapeutics Rejects Merck's $3B Buyout Amid Promising IL-17 Pipeline Merck MoonLake Immunotherapeutics MoonLake Immunotherapeutics has rejected Merck’s $3B acquisition offer, choosing to advance its promising IL-17A/F antibody Sonelokimab, now in Phase III trials for autoimmune diseases like HS and PsA.
Eli Lilly and Camurus Sign $870M Deal for Long-Acting Incretin Therapies Using FluidCrystal® Technology Eli Lilly Camurus Eli Lilly partners with Camurus in an $870M deal to develop long-acting incretin therapies using FluidCrystal® technology, aiming to improve treatment adherence for obesity, diabetes, and chronic diseases.
ASCO 2025: BMS Defends Opdualag's Future After Adjuvant Melanoma Setback BMS ASCO Market Trend Bristol Myers Squibb’s Opdualag failed to improve outcomes in adjuvant melanoma, raising questions about LAG-3 antibodies. Despite this, BMS remains confident in ongoing NSCLC trials targeting PD-1 positive patients.
CDC Official Resigns as COVID Vaccine Guidance Shifts Vaccine HHS FDA The CDC's senior COVID vaccine expert Dr. Lakshmi Panagiotakopoulos has resigned amid shifting U.S. vaccine recommendations. Recent policy changes, including removed guidance for children, have sparked debate among health officials.
Bayer’s Nubeqa Gains FDA Expansion for Broader Prostate Cancer Use Bayer FDA Bayer secures FDA approval to expand Nubeqa's use for all metastatic castration-sensitive prostate cancer patients, including those unable to tolerate chemotherapy, strengthening its position in the prostate cancer treatment market.
Vividion Gains Rights to Covalent WRN Inhibitor VVD-214 from Roche Bayer Vividion Therapeutics Roche Bayer’s Vividion Therapeutics secures exclusive global rights to VVD-214, the only clinical-stage covalent WRN inhibitor, from Roche. The drug shows early promise for treating MSI-high cancers in phase 1 trials.
Bicara and Merus Compete in HNSCC Drug Development Race ASCO Bicara Merus Bicara and Merus are advancing competing therapies for head and neck cancer (HNSCC). While Merus shows strong early OS data, Bicara focuses on long-term outcomes, especially in HPV-negative patients, with a pivotal trial underway.
Proposed NIH Cancer Research Cuts Spark Industry Concern ASCO Trump NIH NCI The Trump administration’s proposed budget cuts to NIH and NCI risk hindering cancer research progress, prompting strong opposition from ASCO and ACS CAN over potential impacts on patient outcomes and innovation.
Kura and Kyowa's Ziftomenib Shows 23% Remission in AML Trial ASCO Market Trend FDA Kura Oncology and Kyowa Kirin announced a 23% remission rate in their phase 2 trial of oral leukemia drug ziftomenib for relapsed/refractory NPM1-mutant AML, with FDA approval under review and phase 3 trials planned.